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EVIDENCE BASED NEURO-ONCOLOGY
The significance of MGMT methylation in Glioblastoma Multiforme prognosis
Aaida Mumtaz Rao, Ayesha Quddusi, Muhammad Shahzad Shamim

Abstract
Methylation of O6-methylguanine-DNA
methyltransferase (MGMT) has been
extensively studied as a biomarker in
predicting the prognosis of patients with GBM
(Glioblastoma multiforme). Its significance has
been studied in various subgroups, including
age, gender and even race. Correlation
between prognosis with MGMT methylation
and different treatment regimens has also
been studied in detail. There are multiple
techniques to analyze MGMT methylation in
tumour specimen. We review the current
evidence for the importance of MGMT
methylation as a biomarker for prognosis in
GBM patients, the techniques to analyze it and
the effect of epidemiologic factors on its
significance.

Figure-1 (a,b): MRI T1WI axial sections with and without contrast, showing a large GBM in right occipital
region.

Keywords: Glioblastoma multiforme, tumour
markers, MGMT methylation.

Background
Glioblastoma is the most common primary brain tumour
in adults. The standard treatment includes surgical
resection, radiotherapy (RT) and chemotherapy, mostly
with alkylating agent Temozolamide (TMZ). Despite
these regimens, prognosis remains poor.1 Various
biomarkers are used to predict prognosis of patients with
GBM.2 Amongst these, methylation of O6methylguanine-DNA methyltransferase (MGMT) is
considered to be a biomarker for good prognosis.3,4
MGMT is a DNA repair protein, that repairs damage from
alkylating agents. Methylation of MGMT gene can silence
its expression, leading to cell death after damage from
alkylating agents that can facilitate cell death of cancer
cells in GBM.5,6

Review of Evidence
One of the initial papers that showed MGMT
methylation status as an independent prognostic factor
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in GBM patients was by Hegi et al. They demonstrated
that MGMT methylation was associated with better
overall survival in GBM patients treated with TMZ plus
RT as well as patients receiving RT alone.7 A recent
meta-analysis of 34 clinical trials concluded that MGMT
methylation was significantly associated with better
overall survival (OS) in patients with GBM.3 This is true
even for tumours that are not suitable for resection.4
For recurrent GBM also not suitable for resection, a
retrospective study by Kim et al., showed correlation of
MGMT promoter methylation status with better
progression free survival (PFS), and OS in patients who
underwent gamma knife radiosurgery. 8 MGMT
methylation, and low MGMT expression were also
identified as favourable prognostic markers in patients
with newly diagnosed GBM, who underwent
implantation of carmustine releasing wafers (Gliadel)
after surgery.9
There are several different techniques available to
analyze MGMT methylation status in GBM tumours.
Christians et al., compared the use of methylation
specific polymerase chain reaction (MSP), methylation
specific
multiplex
ligation-dependent
probe
amplification (MS-MLPA) and pyrosequencing in
methylation analysis of MGMT, and found that
pyrosequencing was the most useful tool in analysis of

1138

A. M. Rao, A. Quddusi, M. S. Shamim

than male patients.15

Conclusion

Figure-2 (a,b): MRI T1WI axial sections with and without contrast of the same patient, showing complete resection of tumor.

MGMT methylation status in terms of predicting clinical
outcome and cost effectiveness when a large number of
samples have to be analyzed. However, MSP was useful
for routine clinical diagnostics with a smaller number of
samples.10
The status of MGMT methylation as a predictive
biomarker in prognosis may be effected by age,
gender, and race. It is an important prognostic factor
for OS, as well as PFS in elderly patients treated with
TMZ and RT. 11 In paediatric GBM studies, MGMT
methylation has also been observed as a predictor of
increased PFS, however these studies have a small
sample size. Rizzo et al., showed that the presence of
MGMT methylation in paediatric population is rare. 12
The importance of MGMT methylation also differs by
area and continents. A recent systematic review and
meta-analysis noted that while MGMT methylation
remained a significant marker of PFS in patients in
different parts of the world, it did not hold the same
significance regarding OS in Asian patients with
MGMT methylation compared to patients in US and
Europe.13 Similarly, in another systematic review and
meta-analysis MGMT promoter methylation had
significant effect on OS in Asian population but not
on PFS, while it had a significant effect on both OS
and PFS in Caucasian population. 14 Gender also
appears to have an impact on the importance of
MGMT methylation in predicting prognosis. In a
recent study, Franceschi et al., observed that female
patients with MGMT methylation had longer survival

MGMT methylation has been
shown to be significantly
associated with PFS and OS in
GBM patients and can be used as
a prognostic marker. There are
several ways to assess it and MSP
as well as pyrosequencing
appear to be good techniques to
analyze MGMT methylation
status. However, GBM biology is
complex and MGMT methylation
is not the only prognostic
biomarker. The current evidence
suggests that epidemiologic
factors such as age, gender and
race also appear to affect its
importance as a marker.
However, there are too few
studies to establish a link here.
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